TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

TGFβ阻断揭示了肿瘤基质的可塑性,表现为存在一类经干扰素激活的成纤维细胞。

阅读:3
作者:Angelo L Grauel ,Beverly Nguyen ,David Ruddy ,Tyler Laszewski ,Stephanie Schwartz ,Jonathan Chang ,Julie Chen ,Michelle Piquet ,Marc Pelletier ,Zheng Yan ,Nathaniel D Kirkpatrick ,Jincheng Wu ,Antoine deWeck ,Markus Riester ,Matt Hims ,Felipe Correa Geyer ,Joel Wagner ,Kenzie MacIsaac ,James Deeds ,Rohan Diwanji ,Pushpa Jayaraman ,Yenyen Yu ,Quincey Simmons ,Shaobu Weng ,Alina Raza ,Brian Minie ,Mirek Dostalek ,Pavitra Chikkegowda ,Vera Ruda ,Oleg Iartchouk ,Naiyan Chen ,Raphael Thierry ,Joseph Zhou ,Iulian Pruteanu-Malinici ,Claire Fabre ,Jeffrey A Engelman ,Glenn Dranoff ,Viviana Cremasco

Abstract

Despite the increasing interest in targeting stromal elements of the tumor microenvironment, we still face tremendous challenges in developing adequate therapeutics to modify the tumor stromal landscape. A major obstacle to this is our poor understanding of the phenotypic and functional heterogeneity of stromal cells in tumors. Herein, we perform an unbiased interrogation of tumor mesenchymal cells, delineating the co-existence of distinct subsets of cancer-associated fibroblasts (CAFs) in the microenvironment of murine carcinomas, each endowed with unique phenotypic features and functions. Furthermore, our study shows that neutralization of TGFβ in vivo leads to remodeling of CAF dynamics, greatly reducing the frequency and activity of the myofibroblast subset, while promoting the formation of a fibroblast population characterized by strong response to interferon and heightened immunomodulatory properties. These changes correlate with the development of productive anti-tumor immunity and greater efficacy of PD1 immunotherapy. Along with providing the scientific rationale for the evaluation of TGFβ and PD1 co-blockade in the clinical setting, this study also supports the concept of plasticity of the stromal cell landscape in tumors, laying the foundation for future investigations aimed at defining pathways and molecules to program CAF composition for cancer therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。